Return patients living with chronic wounds to healing sooner

Abstract

Technology Lipido-Colloid with nano-oligosaccharide factor (TLCNOSF) range’s efficacy in healing significantly sooner has been demonstrated in the highest level of clinical studies (double-blind, randomised controlled trials)^1,2 and through observational  studies.³ These studies have also demonstrated that the earlier the TLC-NOSF (UrgoStart) treatment range is initiated, the more effective it is for complex and first-intention wounds.^2,3